Takeaway
- Compared with teriflunomide, ublituximab (an anticluster of differentiate 20 antibody) reduced relapses and brain lesions, but not disability, among patients with relapsing multiple sclerosis (MS).
Why this matters
- Existing MS treatments have adverse effects, limited efficacy; some require frequent dosing.
Key results
- At 96 weeks, annualized relapse rate, ublituximab...
